Immutep announces response rates from INSIGHT-003 trial

Immutep (IMMP) Limited announces that a 60.8% response rate and 90.2% disease control rate, according to RECIST1.1, has been achieved in the investigator-initiated INSIGHT-003 trial as of the data-cut off date of 06 May 2025. INSIGHT-003 is evaluating eftilagimod alpha in combination with the anti-PD-1 therapy, KEYTRUDA and doublet chemotherapy as first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer. Data from all evaluable patients demonstrates significant improvement of Overall Response Rate according to RECIST 1.1 across all levels of PD-L1 expression compared to historical control from a registrational trial of anti-PD-1 and doublet chemotherapy in non-squamous 1L NSCLC1: 75.0% ORR versus 62.1% ORR in patients with high PD-L1 expression; 64.0% ORR versus 49.2% ORR in patients with low PD-L1 expression; 54.5% ORR versus 32.3% ORR in patients with negative PD-L1 expression,